Insurance is by far the most important factor of whether patients followed up with treatment after getting screened for glaucoma, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Insurance is, by far, the most important factor of whether patients followed up with treatment after getting screened for glaucoma, said Byron L. Lam, MD, professor of ophthalmology, University of Miami Miller School of Medicine's Bascom Palmer Eye Institute.
Transcript
You have published research on the socioeconomic factors impacting glaucoma screening follow-up and insurance was the main culprit. Was it type of insurance or simply being insured vs uninsured?
I think what we found in this paper is that insurance is, by far, the most important factor in terms of follow-up treatment for patients or subjects who receive glaucoma screening. In our subjects who were identified as glaucoma suspect, those who followed up with subsequent treatments and assessments are really the ones who have insurance or a way to get into some sort of insurance. I think this speaks to the fact that glaucoma screening is great; on the other hand, you do have the socioeconomically underprivileged, who don't have insurance. Typically, these will be patients who either are poor, but they are also maybe in a minority group, as well. Some of them may be new immigrants.
We find that in these particular groups, when they don't have insurance, even if you identify them as glaucoma suspect, they really do not get the proper follow-up. I think that's the number one determinant. And I think we need to find a way of, how do we at least provide them with insurance? How do we go ahead and provide care? Because if they have glaucoma that's untreated and they have visual loss, well, they're not going to be able to work; that will be an additional burden to the society.
It's not as though “Oh, we're going to give them free health care,” but it's more like, we need to have some way that they can obtain health insurance through their employment or some way, so that they do not become a burden to society, as well as have better lives.
What were other factors associated with noncompliance with the program?
I think for noncompliance, there were many factors. One, of course, is that some of the subjects are not really acculturated. If you come to a country and you're not really understanding or have relatives and friends who can help you with the systems at work, with health systems, of how to make an appointment, and so forth, you're going to be in a difficult position, even if information is given to you. I think that is also associated with socioeconomic status. I think that's one important determinant.
Then I think the other point associated with that, it's just difficult understanding a condition when you don't have any symptoms. It’s also depending on your educational level, and then your background. I think it all comes down to socioeconomic level, and also that is linked to acculturation.
Reference
Staropoli PC, Lee RK, Kroger ZA, et al. Analysis of socioeconomic factors affecting follow-up in a glaucoma screening program. Clin Ophthalmol. 2021;15:4855-4863. doi:10.2147/OPTH.S346443
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More